Westfield Capital Management Co. LP Invests $30.40 Million in Merus (NASDAQ:MRUS)

Westfield Capital Management Co. LP purchased a new stake in Merus (NASDAQ:MRUS - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 608,457 shares of the biotechnology company's stock, valued at approximately $30,399,000. Westfield Capital Management Co. LP owned 0.89% of Merus as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently modified their holdings of MRUS. GSA Capital Partners LLP acquired a new stake in Merus in the third quarter valued at $675,000. Driehaus Capital Management LLC grew its position in shares of Merus by 26.4% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,550,009 shares of the biotechnology company's stock valued at $91,714,000 after buying an additional 323,518 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Merus in the first quarter valued at about $555,000. D. E. Shaw & Co. Inc. raised its position in shares of Merus by 90.6% during the second quarter. D. E. Shaw & Co. Inc. now owns 521,339 shares of the biotechnology company's stock worth $30,848,000 after acquiring an additional 247,813 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of Merus in the first quarter worth approximately $53,377,000. Institutional investors own 96.14% of the company's stock.

Merus Stock Down 0.2 %

MRUS traded down $0.10 during trading on Monday, hitting $45.39. 505,149 shares of the company's stock were exchanged, compared to its average volume of 683,903. Merus has a fifty-two week low of $22.26 and a fifty-two week high of $61.61. The stock has a market cap of $3.11 billion, a P/E ratio of -11.65 and a beta of 1.12. The business's 50 day moving average is $50.39 and its two-hundred day moving average is $51.85.

Merus (NASDAQ:MRUS - Get Free Report) last posted its earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.05). The business had revenue of $11.77 million during the quarter, compared to analyst estimates of $9.11 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. On average, sell-side analysts forecast that Merus will post -3.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MRUS. UBS Group assumed coverage on shares of Merus in a report on Thursday, October 24th. They set a "buy" rating and a $72.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $85.00 price target on shares of Merus in a research report on Wednesday, November 20th. HC Wainwright reissued a "buy" rating and issued a $85.00 price objective on shares of Merus in a research report on Friday, November 1st. The Goldman Sachs Group assumed coverage on Merus in a research note on Thursday. They set a "buy" rating and a $73.00 target price for the company. Finally, Lifesci Capital raised Merus to a "strong-buy" rating in a research note on Monday, July 29th. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $85.45.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.